How Mistrust and Violence Are Undermining the 2026 Ebola Response in DR Congo

A WHO-convened Technical Advisory Group has identified several candidates as “promising enough” for clinical trials, including the monoclonal antibodies MBP134 and maftivimab, along with the antivirals remdesivir and obeldesivir. However, the group explicitly recommended that these products be used exclusively within clinical trial protocols to generate robust safety and efficacy data . The most promising vaccine candidate, a single-dose rVSV Bundibugyo shot from IAVI, is still seven to nine months away from efficacy trials .

Violence Against the Front Lines

This lack of a silver bullet makes standard public health measures — case identification, contact tracing, and safe burials — the only way to stop transmission. Yet those very activities have become flashpoints for violence.

On June 1, a safe burial team was assaulted in Katana, South Kivu, forcing responders to abandon a coffin . That same day, 11 Ebola patients fled isolation facilities in the same region, raising immediate fears of new transmission chains . This attack followed a pattern: on May 21, youths stormed an ALIMA-run treatment center in Rwampara and set it on fire after officials refused to release the body of a victim for a traditional family burial . The next day, an MSF tent in Mongwalu was also torched, and 18 suspected Ebola patients fled, unaccounted for at the time . Within a matter of days, two treatment centers in the region had been burned to the ground .

Burial teams, who are trained to handle highly infectious bodies, now require military and police escorts in Ituri province, turning a public health function into a security operation .